UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data

MT Newswires Live11-06

UroGen Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer can support the submission of a new drug application.

Initial results from the study showed a 77.8% three-month complete response rate, which is consistent with the 79.6% three-month complete response rate after treatment with UroGen's FDA-approved bladder cancer drug Zusduri in a pivotal trial, according to a statement.

The company said it is preparing for an NDA submission in 2026.

UroGen said UGN-103 will have a shorter manufacturing process and simplified reconstitution procedure compared with Zusduri.

Shares of UroGen were up more than 3% in recent trading Thursday.

Price: 19.92, Change: +0.61, Percent Change: +3.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581970500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581970500","market":"fut","top_or_hot":-1,"title":"UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer can support the submission of a new drug application.</p><p>Initial results from the study showed a 77.8% three-month complete response rate, which is consistent with the 79.6% three-month complete response rate after treatment with UroGen's FDA-approved bladder cancer drug Zusduri in a pivotal trial, according to a statement.</p><p>The company said it is preparing for an NDA submission in 2026.</p><p>UroGen said UGN-103 will have a shorter manufacturing process and simplified reconstitution procedure compared with Zusduri.</p><p>Shares of UroGen were up more than 3% in recent trading Thursday.</p><p>Price: 19.92, Change: +0.61, Percent Change: +3.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-06 23:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer can support the submission of a new drug application.</p><p>Initial results from the study showed a 77.8% three-month complete response rate, which is consistent with the 79.6% three-month complete response rate after treatment with UroGen's FDA-approved bladder cancer drug Zusduri in a pivotal trial, according to a statement.</p><p>The company said it is preparing for an NDA submission in 2026.</p><p>UroGen said UGN-103 will have a shorter manufacturing process and simplified reconstitution procedure compared with Zusduri.</p><p>Shares of UroGen were up more than 3% in recent trading Thursday.</p><p>Price: 19.92, Change: +0.61, Percent Change: +3.16</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581970500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581970500","pubTimestamp":1762443389,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UroGen Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in re","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","URGN":"乌龙制药"},"translate_title":"UroGen表示FDA根据3期数据同意UGN-103的新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"UroGen Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer can support the submission of a new drug application.Initial results from the study showed a 77.8% three-month complete response rate, which is consistent with the 79.6% three-month complete response rate after treatment with UroGen's FDA-approved bladder cancer drug Zusduri in a pivotal trial, according to a statement.The company said it is preparing for an NDA submission in 2026.UroGen said UGN-103 will have a shorter manufacturing process and simplified reconstitution procedure compared with Zusduri.Shares of UroGen were up more than 3% in recent trading Thursday.Price: 19.92, Change: +0.61, Percent Change: +3.16","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581970500","isCrawlerRequest":true}